申请人:Dainippon Pharmaceutical Co., Ltd.
公开号:US04442101A1
公开(公告)日:1984-04-10
Novel 1-ethyl-6-fluoro-1,4-dihyono-4-oxo -7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid.sesquihydrate (ATT-2266.sesquihydrate). The aforesaid compound can be prepared by heating 1-ethyl-6-fluoro-1,4-dihydro-4-oxo -7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid at a temperature above about 60.degree. C. in the presence of water in an amount sufficient to form the sesquihydrate. This sesquihydrate is much more stable than the anhydrate and the trihydrate and is superior to the anhydrate in the rate of dissolution and transference into the body through the intestines. Thus, it is especially useful as a pharmaceutical compound.
1-乙基-6-氟-1,4-二氢-4-氧基-7-(1-哌嗪基)-1,8-萘啶-3-羧酸倍水合物(ATT-2266倍水合物)。上述化合物可以通过在水的存在下将1-乙基-6-氟-1,4-二氢-4-氧基-7-(1-哌嗪基)-1,8-萘啶-3-羧酸加热至60摄氏度以上来制备倍水合物。这种倍水合物比无水物和三水合物更稳定,并且在溶解速度和通过肠道进入体内的转移速度方面优于无水物。因此,它在制药领域中具有特殊的用途。